March 16, 2026 Insider Pick Spotlight
Top insider-buy setups from today's qualified signals.
Today’s Qualified Filing
One filing after the close passed our filters.
MBX Biosciences (MBX)
Company: MBX Biosciences (MBX)
Insider: P. Kent Hawryluk, President and CEO
Transaction: Open-market purchase of 18,500 shares at about $28.41
Estimated Value: about $525,585
Timing: Trade date March 13; filed after the close on March 16
52-Week Range Position
- 52-week low: about $4.81
- 52-week high: about $44.89
At current levels, MBX sits in the middle of its 52-week range and is not near a 52-week low.
Recent News Context
Recent updates likely supporting sentiment around the purchase:
- Quarterly results reportedly beat consensus EPS expectations
- Positive clinical data for the hypoparathyroidism program
- Company plans to initiate a Phase 3 trial in 2026
Filing Context
The purchase price and later market price are filing context only. They are not a prediction, recommendation, tracked return, or proof that the signal worked.
Research note only. Not personalized investment advice. All investing involves risk, including loss of principal.